ClinicalTrials.gov
ClinicalTrials.gov Menu

Stratus Versus Cirrus OCT in AMD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00568191
Recruitment Status : Unknown
Verified December 2007 by The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery.
Recruitment status was:  Recruiting
First Posted : December 5, 2007
Last Update Posted : December 5, 2007
Sponsor:
Information provided by:
The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The Cirrus OCT provides due to the spectral domain technology a 2-fold resolution than Stratus OCT generated in a comparable amount of time. Due to this higher resolution the retinal surface and the retinal pigment epithelium can be identified more clearly, a significantly reduced number of algorithm failures is expected

Condition or disease
Age-Related Macular Degeneration Choroidal Neovascularization

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Reliability of Threshold Algorithm in Age-Related Macular Degeneration: Stratus Versus Cirrus OCT
Study Start Date : October 2007
Estimated Study Completion Date : December 2007

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
1
retinal thickness program Stratus OCT software 4.0
2
retinal cube 200x200 program of Cirrus OCT


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Number of algorithm failures assessed by Stratus OCT versus Cirrus OCT in the horizontal central line [ Time Frame: only 1 examination ]

Secondary Outcome Measures :
  1. Number of algorrithm failures in Stratus versus Cirrus OCT assessed in the whole scan [ Time Frame: 1 examination ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   55 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients aged > 55 years of either sex presenting with age-related macular degeneration
Criteria

Inclusion Criteria:

  • Age>55 years
  • Age-related macular degeneration

Exclusion Criteria:

  • Not consented patients
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00568191


Contacts
Contact: Ilse Krebs, MD +43171165 ext 94607 Ilse.Krebs@wienkav.at

Locations
Austria
Ludwig Boltzmann Institute for Retinology and Biomicroscopic Lasersurgery Recruiting
Vienna, Austria, A1030
Contact: Ilse Krebs, MD    +43171165 ext 4607    Ilse.Krebs@wienkav.at   
Principal Investigator: Ilse Krebs, MD         
Sponsors and Collaborators
The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Investigators
Principal Investigator: Ilse Krebs Ludwig Boltzmann Institute of Retinology and Biomicroscopic Lasersurgery
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Prof Susanne Binder, The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
ClinicalTrials.gov Identifier: NCT00568191     History of Changes
Other Study ID Numbers: EK 06-007-VK1
First Posted: December 5, 2007    Key Record Dates
Last Update Posted: December 5, 2007
Last Verified: December 2007

Keywords provided by The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery:
Age-related macular degeneration
choroidal neovascularization
Stratus OCT
Cirrus OCT

Additional relevant MeSH terms:
Macular Degeneration
Neovascularization, Pathologic
Choroidal Neovascularization
Retinal Degeneration
Retinal Diseases
 Eye Diseases
Metaplasia
Pathologic Processes
Choroid Diseases
Uveal Diseases